Novavax announced Monday in a news release that it had completed a rolling submission to Health Canada for authorization of its two-dose COVID-19 vaccine, a long-awaited development for the Maryland companyThe insensitivity,, which has struggled to bring its doses for use in the global inoculation campaign.
Shares of Novavax rose about 11 per cent before the opening bell after the company also said it had filed an application for emergency use for the vaccine to Canada as well as the European Medicines Agency:1618426651162,.
“Novavax continues to deliver regulatory filings that we expect will bring the first protein-based COVID-19 vaccine based on Phase 3 data to the worldEven if you get a few hundred people that can go for a few weeks,” Stanley CThe commercial real estate company.. ErckThe end of May., Novavax’s president and chief executive officerFrance Rochette, said in a statement:1618310820928,.
Meanwhile, Novavax got its first approval anywhere in the world on Monday, when the company and partner Serum received emergency-use authorization for their COVID-19 vaccine in Indonesiawhich has been criticized as sluggish.
Copyright © 2011 JIN SHI